Option Care Health (OPCH) UBS Global Healthcare Conference 2025 summary

Executive insights and business overview

• Leadership transition highlighted a strong cultural fit and alignment with the company's mission to serve patients and families.

• The business operates as the largest independent home and alternate site infusion services provider, serving nearly 300,000 patients annually across all 50 states with 170 sites.

• Revenue has grown at a 13% CAGR, EBITDA at 19%, and operating cash flow at 26% since 2020.

• The company maintains broad payer coverage, including the top 10 payers, and strong pharma partnerships.

Financial performance and guidance

• Adjusted EBITDA guidance was raised by $15 million and adjusted EPS by $0.06 for the year, with confidence in full-year 2025 guidance.

• Despite headwinds from STELARA, double-digit growth in chronic sales was achieved, and the long-term growth algorithm remains intact.

• 2026 is expected to see continued growth, with management confident in mitigating ongoing headwinds.

• No other drug concentration is as significant as STELARA; branded drugs make up 50% of revenue but only 25% of profit.

STELARA and biosimilar dynamics

• STELARA restructuring led to a $60–70 million gross profit headwind in 2025 due to changes in discount rates and biosimilar launches.

• Biosimilars entered the market at lower price points, impacting revenue but not derailing overall growth.

• Ongoing negotiations with Janssen and biosimilar manufacturers are expected to clarify 2026 impacts, with updates planned as visibility improves.